MANNKIND CORP

MNKD ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Revenue $349.0M $285.5M $199.0M $99.8M $75.4M $65.1M $63.0M
Cost of Revenue $26.8M $17.4M $20.9M $16.0M $16.8M $15.1M $20.1M
Gross Profit $322.2M $268.1M $178.1M $83.8M $58.6M $50.1M $43.0M
Gross Margin 92.3% 93.9% 89.5% 84.0% 77.7% 76.8% 68.1%
Operating Expenses
Research & Development
SG&A Expense $144.1M $94.3M $94.3M $91.5M $77.4M $59.0M $74.7M
Operating Income $38.8M $72.6M $8.7M $-64.1M $-47.0M $-47.9M $-44.6M
Operating Margin 11.1% 25.4% 4.4% -64.3% -62.3% -73.5% -70.7%
Interest Expense $15.2M $15.0M $15.2M $9.5M $6.3M
Pretax Income $1.4M $30.5M $-10.4M $-87.4M $-80.9M $-57.5M $-51.9M
Income Tax Expense $-4.5M $2.9M $1.6M $0 $0 $-218.0K $0
Net Income $5.9M $27.6M $-11.9M $-87.4M $-80.9M $-57.2M $-51.9M
Net Margin 1.7% 9.7% -6.0% -87.6% -107.3% -87.9% -82.3%
EPS (Basic) $0.02 $0.10 $-0.04 $-0.34 $-0.32 $-0.26 $-0.27
EPS (Diluted) $0.02 $0.10 $-0.04 $-0.34 $-0.32 $-0.26 $-0.27
Shares Outstanding (Basic) 308.1M 305.6M 274.4M 267.0M 257.1M 249.2M 222.6M 211.8M
Shares Outstanding (Diluted) 308.1M 314.1M 283.8M 267.0M 257.1M 249.2M 222.6M 211.8M
Dividends Per Share
← Newer Page 1 of 5 Older →